Moderna, Inc.
MRNA Healthcare Biotechnology
Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.11%, EPS grew 7.51%, free cash flow grew 38.9% and total debt rose 1,765.6%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100.
Follow MRNA
Moderna, Inc. (MRNA) Revenue
Moderna, Inc.'s revenue for fiscal 2025 was $1.9B, down 39.9% from $3.2B in fiscal 2024. Over the twelve months to 30 June 2026 it was $2.2B. Over the past ten years it has ranged from $60.0M (fiscal 2019) to $19.3B (fiscal 2022); the current reading is higher than 60% of that period. Revenue has fallen for 3 consecutive fiscal years. Moderna, Inc. ranks 14th of 401 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.9B | (39.93%) |
| FY2024 | $3.2B | (52.75%) |
| FY2023 | $6.8B | (64.45%) |
| FY2022 | $19.3B | 4.29% |
| FY2021 | $18.5B | 2,200.25% |
| FY2020 | $803.0M | 1,238.33% |
| FY2019 | $60.0M | (55.58%) |
| FY2018 | $135.1M | (34.38%) |
| FY2017 | $205.8M | 89.88% |
| FY2016 | $108.4M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $145.0M | (62.72%) |
| Mar 2026 | $389.0M | (42.63%) |
| Dec 2025 | $678.0M | (33.27%) |
| Sep 2025 | $1.0B | 615.49% |
| 30 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $15.5B |
| VRTX Vertex Pharmaceuticals Incorporated compare | $12.6B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.1B |
| ARGX argenex SE compare | $5.3B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $4.8B |
| RPRX Royalty Pharma PLC compare | $2.5B |
| MRNA Moderna, Inc. | $2.2B |
| RVMD Revolution Medicines, Inc. compare | $26.9M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on MRNA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement